scholarly journals Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals

2021 ◽  
Vol 98 (1) ◽  
pp. 18-27
Author(s):  
D. E. Valutite ◽  
A. V. Semenov ◽  
Yu. V. Ostankova ◽  
K. V. Kozlov ◽  
A. G. Borisov ◽  
...  

Background. The development of direct acting antivirals (DAAs) has spurred a revolution in treatment of patients with chronic hepatitis C. However, there are cases showing no response to treatment. In 5% of cases, the viral breakthrough is most likely caused by DAA resistance mutations in the hepatitis C virus genome.The purpose of the study is to detect drug resistance mutations of hepatitis C virus in patients with DAA treatment failure.Materials and methods. The study was performed on plasma samples from 3 patients diagnosed with chronic hepatitis C virus infection and demonstrating DAA virological treatment failure. All isolates had genotype 1b. Drug resistance mutations were detected by using direct sequencing of NS3, NS5A, and NS5B genome regions. The detection technique was developed at the Pasteur Research Institute of Epidemiology and Microbiology.Results. Drug resistance mutations were detected in all cases. By using the Geno2pheno [hcv] 0.92 tool, nucleotide substitutions were detected in different viral genome regions and presumably caused resistance or decreased sensitivity to antivirals both present and absent in the sofosbuvir + daclatasvir combination therapy. Antiviral treatment failure in patients with chronic hepatitis C is caused by drug resistance mutations.Conclusions. The developed technique is efficient for detection of drug resistance mutations in NS3, NS5A, and NS5B regions in cases of virological failure of DAA treatment.

2015 ◽  
Vol 2 (3) ◽  
pp. 285-295 ◽  
Author(s):  
Dapeng Li ◽  
Zhong Huang ◽  
Jin Zhong

Abstract Hepatitis C virus (HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents (DAAs), but the worldwide use of these highly effective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. Therefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an effective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an effective HCV vaccine.


PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0229994
Author(s):  
Sheng Feng Lin ◽  
Shui-Yi Tung ◽  
Kuo-Liang Wei ◽  
Chien-Hung Chen ◽  
Tsung-Hui Hu ◽  
...  

2016 ◽  
Vol 50 ◽  
pp. 1-5 ◽  
Author(s):  
Elif Sargin Altunok ◽  
Murat Sayan ◽  
Sila Akhan ◽  
Bilgehan Aygen ◽  
Orhan Yildiz ◽  
...  

2015 ◽  
Vol 156 (21) ◽  
pp. 841-848
Author(s):  
Gábor Horváth ◽  
Tünde Halász ◽  
Mihály Makara ◽  
Béla Hunyady

Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal. Orv. Hetil., 2015, 156(21), 841–848.


2019 ◽  
Vol 09 (10) ◽  
pp. 193-201
Author(s):  
Dimitri Hatrydt Kouamé ◽  
Stanislas Adjéka Doffou ◽  
Henriette Kissi Anzouan-Kacou ◽  
Yannick Mfupa Tchana ◽  
Aboubakar Demba Bangoura ◽  
...  

JGH Open ◽  
2020 ◽  
Vol 4 (4) ◽  
pp. 713-721
Author(s):  
Riccardo Nevola ◽  
Luca Rinaldi ◽  
Letizia Zeni ◽  
Ferdinando C Sasso ◽  
Pia C Pafundi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document